CL2021000282A1 - Inhibidores de ckd8/19 - Google Patents
Inhibidores de ckd8/19Info
- Publication number
- CL2021000282A1 CL2021000282A1 CL2021000282A CL2021000282A CL2021000282A1 CL 2021000282 A1 CL2021000282 A1 CL 2021000282A1 CL 2021000282 A CL2021000282 A CL 2021000282A CL 2021000282 A CL2021000282 A CL 2021000282A CL 2021000282 A1 CL2021000282 A1 CL 2021000282A1
- Authority
- CL
- Chile
- Prior art keywords
- inhibitors
- ckd8
- compounds
- cdk8
- disorders
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2018128415A RU2761824C2 (ru) | 2018-08-03 | 2018-08-03 | Ингибиторы CDK8/19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2021000282A1 true CL2021000282A1 (es) | 2021-08-13 |
Family
ID=69231230
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2021000282A CL2021000282A1 (es) | 2018-08-03 | 2021-02-02 | Inhibidores de ckd8/19 |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US11840531B2 (https=) |
| EP (1) | EP3831829A4 (https=) |
| JP (1) | JP7365396B2 (https=) |
| KR (1) | KR102926889B1 (https=) |
| CN (1) | CN113166140B (https=) |
| AR (1) | AR115898A1 (https=) |
| AU (1) | AU2019313199B2 (https=) |
| BR (1) | BR112021001939A2 (https=) |
| CA (1) | CA3108298A1 (https=) |
| CL (1) | CL2021000282A1 (https=) |
| CO (1) | CO2021001174A2 (https=) |
| EA (1) | EA202190452A1 (https=) |
| MA (1) | MA52375B2 (https=) |
| MX (1) | MX2021001335A (https=) |
| PE (1) | PE20210416A1 (https=) |
| PH (1) | PH12021550258A1 (https=) |
| RU (1) | RU2761824C2 (https=) |
| TW (1) | TWI839374B (https=) |
| WO (1) | WO2020027704A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023533016A (ja) | 2020-07-11 | 2023-08-01 | ファイザー・インク | 抗ウイルス性ヘテロアリールケトン誘導体 |
| US11351149B2 (en) | 2020-09-03 | 2022-06-07 | Pfizer Inc. | Nitrile-containing antiviral compounds |
| WO2024109660A1 (zh) * | 2022-11-21 | 2024-05-30 | 上海齐鲁制药研究中心有限公司 | Cdk抑制剂 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR060358A1 (es) * | 2006-04-06 | 2008-06-11 | Novartis Vaccines & Diagnostic | Quinazolinas para la inhibicion de pdk 1 |
| MX2010006244A (es) * | 2007-12-06 | 2010-12-02 | Schering Corp | Moduladores de gamma secretasa. |
| CN103249721B (zh) * | 2010-10-18 | 2016-10-12 | 拉夸里亚创药株式会社 | 作为ttx-s阻滞剂的芳胺衍生物 |
| TWI529171B (zh) * | 2013-07-29 | 2016-04-11 | 赫孚孟拉羅股份公司 | １，７－萘啶衍生物 |
| JP2017522324A (ja) | 2014-07-17 | 2017-08-10 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | 新規ナフチリジン及びイソキノリンならびにｃｄｋ８／１９阻害剤としてのその使用 |
| EP3383875B1 (en) * | 2015-11-30 | 2022-02-09 | Council Of Scientific & Industrial Research | 3-pyrimidinyl pyrrolo [2,3-b] pyridine as anticancer agents and the process for the preparation thereof |
| US11213520B2 (en) * | 2016-05-23 | 2022-01-04 | Boehringer Ingelheim International Gmbh | Phenylpyrazolylacetamide compounds and derivatives as CDK8/CDK19 inhibitors |
-
2018
- 2018-08-03 RU RU2018128415A patent/RU2761824C2/ru active
-
2019
- 2019-07-31 MA MA52375A patent/MA52375B2/fr unknown
- 2019-07-31 PE PE2021000162A patent/PE20210416A1/es unknown
- 2019-07-31 US US17/264,670 patent/US11840531B2/en active Active
- 2019-07-31 MX MX2021001335A patent/MX2021001335A/es unknown
- 2019-07-31 AU AU2019313199A patent/AU2019313199B2/en active Active
- 2019-07-31 WO PCT/RU2019/050123 patent/WO2020027704A1/ru not_active Ceased
- 2019-07-31 KR KR1020217006527A patent/KR102926889B1/ko active Active
- 2019-07-31 EP EP19844331.9A patent/EP3831829A4/en active Pending
- 2019-07-31 JP JP2021505964A patent/JP7365396B2/ja active Active
- 2019-07-31 CA CA3108298A patent/CA3108298A1/en active Pending
- 2019-07-31 CN CN201980065665.1A patent/CN113166140B/zh active Active
- 2019-07-31 BR BR112021001939-1A patent/BR112021001939A2/pt unknown
- 2019-07-31 EA EA202190452A patent/EA202190452A1/ru unknown
- 2019-08-02 TW TW108127569A patent/TWI839374B/zh active
- 2019-08-02 AR ARP190102200A patent/AR115898A1/es unknown
-
2021
- 2021-02-02 CL CL2021000282A patent/CL2021000282A1/es unknown
- 2021-02-02 CO CONC2021/0001174A patent/CO2021001174A2/es unknown
- 2021-02-03 PH PH12021550258A patent/PH12021550258A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW202012406A (zh) | 2020-04-01 |
| AU2019313199A1 (en) | 2021-03-11 |
| RU2018128415A (ru) | 2020-02-04 |
| PE20210416A1 (es) | 2021-03-04 |
| CO2021001174A2 (es) | 2021-02-26 |
| BR112021001939A2 (pt) | 2021-04-27 |
| MX2021001335A (es) | 2021-04-12 |
| CN113166140B (zh) | 2024-06-14 |
| CN113166140A (zh) | 2021-07-23 |
| EP3831829A1 (en) | 2021-06-09 |
| RU2761824C2 (ru) | 2021-12-13 |
| JP7365396B2 (ja) | 2023-10-19 |
| AR115898A1 (es) | 2021-03-10 |
| AU2019313199B2 (en) | 2023-07-06 |
| RU2018128415A3 (https=) | 2021-03-30 |
| EA202190452A1 (ru) | 2021-04-13 |
| US11840531B2 (en) | 2023-12-12 |
| MA52375B2 (fr) | 2023-02-28 |
| PH12021550258A1 (en) | 2021-10-11 |
| WO2020027704A1 (ru) | 2020-02-06 |
| TWI839374B (zh) | 2024-04-21 |
| MA52375A1 (fr) | 2021-12-31 |
| US20210246138A1 (en) | 2021-08-12 |
| KR102926889B1 (ko) | 2026-02-19 |
| EP3831829A4 (en) | 2022-04-20 |
| CA3108298A1 (en) | 2020-02-06 |
| KR20210040416A (ko) | 2021-04-13 |
| JP2021533143A (ja) | 2021-12-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2021000907A1 (es) | Nuevas piridopirimidinonas sustituidas con bencilamino y derivados como inhibidores de sos1 (divisional de solicitud n° 01501-2020) | |
| CL2021000382A1 (es) | Compuestos novedosos de sulfonamidaurea | |
| MX2021006421A (es) | Anilidas de aminoácidos como moduladores de moléculas pequeñas de interleucinas-17 (il-17). | |
| CL2020002146A1 (es) | Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el cáncer. | |
| MX2020005841A (es) | Derivados de 1,2,4-oxadiazol como inhibidores de histona-desacetilasa 6. | |
| ECSP16005566A (es) | Sulfonamidas como moduladores de canales de sodio | |
| MX2019012847A (es) | Compuestos de c5-anilinoquinazolina y su uso en el tratamiento del cancer. | |
| MX359882B (es) | Amidas como moduladores de canales de sodio. | |
| CU20190101A7 (es) | Imidazopirimidinas diazabicíclicas sustituidas | |
| CL2022000005A1 (es) | Inhibidores de monoacilglicerol lipasa (magl) heterocíclicos | |
| MX2021004566A (es) | Compuestos terapeuticos. | |
| UY36875A (es) | Composiciones inhibidoras de bromodominios para el tratamiento de diversas enfermedades | |
| UY37837A (es) | Nuevos compuestos heterocíclicos como inhibidores de cdk8/19 | |
| EA201891379A1 (ru) | Ингибиторы тирозинкиназы брутона и способы их применения | |
| CL2021000282A1 (es) | Inhibidores de ckd8/19 | |
| MX2020010552A (es) | Derivados de bumetanida para el tratamiento de la hiperhidrosis. | |
| CL2018001631A1 (es) | Compuestos de dihidroquinolinsulfonamida de alquilo | |
| CL2019002480A1 (es) | Derivados de pirazol como inhibidores de bromodominio. | |
| UY37729A (es) | NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7 | |
| UY38133A (es) | Nuevos inhibidores de cdk8/19 | |
| CL2017002229A1 (es) | Inhibidores de bace1. | |
| MX2021003888A (es) | Nuevos compuestos utiles para el tratamiento de enfermedades cardiovasculares. | |
| CL2017001602A1 (es) | Derivados de fumagilol. | |
| UY31989A (es) | Nuevos derivados | |
| CL2020002398A1 (es) | Inhibidores de secreción de proteínas basados en triazaciclododecansulfonamida ("tcd") |